Ryvu Therapeutics Launches Keelira, a Specialized CRO for European Phase I/II Oncology Development
核心洞察
Ryvu Therapeutics (搜索) has launched Keelira (搜索), a Poland-based contract research organization focused on Phase I/II oncology, hematology-oncology, and rare cancer programs in Europe.
Keelira (搜索) uses a "CRO Plus" model combining clinical execution, strategic advisory, and a GCLP-compliant central laboratory to support biotech and pharma sponsors, including those from the US and China.
External client programs will be managed separately from Ryvu's internal drug development under dedicated quality management, data-management, and governance arrangements.
Ryvu Therapeutics (搜索) has announced the launch of Keelira (搜索), a new contract research organization (CRO) business designed to support pharmaceutical and biotechnology companies bringing early-stage oncology programs into European clinical development. Based in Poland, Keelira will focus on Phase I and Phase II programs across oncology, hematology-oncology, and rare cancers, offering an integrated, sponsor-side approach for companies—including those based in the US and China—seeking to extend their oncology pipelines into Europe.
Keelira (搜索) will combine an established operating base in key European markets with the capacity to extend studies across additional EU and non-EU countries as individual programs require. Ryvu has positioned Keelira as a specialized external services company, distinct from its own internal drug development processes.
A "CRO Plus" Service Model
Keelira (搜索) operates under what Ryvu describes as a "CRO Plus" model, placing clinical execution at the core while combining strategic advisory and central laboratory capabilities within a single team. The strategic advisory service aims to integrate clinical execution, data readiness, CMC considerations, and regulatory requirements into a coordinated development plan, ensuring that the development strategy translates into an actionable clinical plan.
At launch, the central laboratory will offer GCLP-compliant sample management and storage, with plans to expand into integrated pharmacokinetics, pharmacodynamics, and biomarker analysis.
Dr Kamil Sitarz, General Manager of Keelira (搜索), explained the rationale behind the integrated approach: "Bringing an oncology programme into Europe requires regulatory strategy, development planning, site selection and clinical execution to move together from the outset." He added that Keelira gives sponsors "one coordinated team across these workstreams: they retain control of the asset, strategy and key decisions, while we take responsibility for execution."
Separation from Ryvu's Internal Programs
Ryvu stressed that external client programs would be managed separately from its internal drug-development activities. The organization has established dedicated quality management procedures, separate data-management arrangements, and client-specific governance to keep external and internal programs apart.
The launch signifies Ryvu's expansion beyond its own drug development operations into a specialized services model for outside pharmaceutical and biotech clients, leveraging the company's expertise in clinical research and oncology drug development to open new revenue opportunities.
Market Context and Industry Impact
The introduction of Keelira (搜索) reflects the growing significance of contracted clinical development services within the biotech and pharmaceutical sectors. According to Precedence Research, the global contract research organization (CRO) services market was calculated at USD 77.00 billion in 2025 and is predicted to increase from USD 82.90 billion in 2026 to approximately USD 158.58 billion by 2035, growing at a CAGR of 7.49% from 2026 to 2035.
The global oncology market was calculated at USD 250.88 billion in 2025 and is predicted to increase from USD 279.73 billion in 2026 to approximately USD 732.45 billion by 2035, expanding at a CAGR of 11.31% from 2026 to 2035.
Keelira (搜索)'s emphasis on rare malignancies, hematology, and oncology is particularly significant because these therapeutic areas frequently require specialized clinical knowledge throughout development programs. Oncology studies may involve complex patient populations, specialized research facilities, biomarker-based patient selection, and thorough safety and efficacy evaluations—factors that can make early clinical development operationally challenging for emerging biotechnology companies.
By focusing on specific therapeutic areas rather than offering comprehensive CRO support across all categories, Keelira (搜索) aims to provide a more specialized service model. Precedence Research identifies oncology as a top application within the CRO services industry, and Europe is recognized as a significant market for CRO services due to its well-established healthcare infrastructure, pharmaceutical capabilities, regulatory frameworks, and research activities.
The development may also encourage greater demand for specialized CROs with expertise in therapeutic areas such as oncology, rare diseases, and hematological cancers. As drug development programs become more specialized and oncology pipelines progressively integrate biomarkers and patient-specific treatment approaches, sponsors may increasingly prefer partners with deep therapeutic and regional knowledge.